Universal Ibogaine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022
For the nine months, sales was CAD 0.939604 million. Net loss was CAD 3.94 million compared to CAD 2.69 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.03 a year ago.